

Recent Breakthroughs in mRNA-based Cancer Vaccines: Structure, Delivery, and Immunotherapeutic Potential

Chihhan Chen

*Science Faculty, Hong Kong University, Hong Kong, China
u3644468@connect.hku.hk*

Abstract. In recent years, messenger RNA (mRNA) has stepped into the spotlight—not only as an important weapon against viruses, but also as a real hope for cancer treatment. And, what once was regarded as too delicate or too avanguardistic has come of age to be one of the most hopeful platforms in contemporary medicine. mRNA cancer vaccine do this by providing instructions to the human's bodies, which in turn instructs the human's cells to make particular antigens that are associated with cancer and better stimulate the immune system to identify and fight only those tumors. This is thanks to several lessons from COVID-19 vaccine development, which allowed scientists to stabilize mRNA at temperatures that were previously unimaginable, change the way they delivered it, and also enhance its effectiveness. Today, state-of-the-art delivery methods such as lipid nanoparticles sufficiently hone in on immune cells mandating extra mRNA with structural modifications allowing enough persistence and translatability. But early clinical trials have indicated signs of hope in difficult to treat cancers like melanoma, lung cancer, and many others. While the human still have years of hard work ahead—addressing tumor complexity and target selection continue to be a challenge—the energy in the field is palpable. In this review, the human shall examine how much benefit have been reaped from mRNA-based cancer vaccines thus far, why they are novel and may even be considered as one of the most exciting frontiers in personalized cancer care.

Keywords: cancer vaccines, lipid nanoparticles, immune checkpoint, RNA modification, tumor immunotherapy

1. Introduction

Nowadays, cancer is one of the most scariest diseases. Despite surgery, radiation and chemotherapy is progressed through decades, many patients still face debilitating side effects and prognosis. These traditional treatments are often lack of specificity—they target both healthy and malignant cells, which bring collateral damage and weakens patients physically and mentally. Moreover, heterogeneity and resistance mechanisms limit long-term efficacy. In recent years, the field of immunotherapy has renewed patients' hope, with the method of leverage using the patient's own immune system to fight with cancer. Checkpoint inhibitors are changing the course of this therapy and CAR-T cells are revolutionizing it. But it also have important drawbacks like cost, difficult manufacturing and for only few tumor is useful. As the field of medicine increasingly shifts toward

immune-based therapies, messenger RNA (mRNA) technology has rapidly risen to prominence. Although initially regarded with skepticism—mainly due to its instability and potential to provoke immune reactions—this perception changed dramatically during the COVID-19 pandemic. Scientists successfully developed and tested mRNA vaccines. This unprecedented achievement not only demonstrated the speed and adaptability of mRNA platforms but also redefined the possibilities of vaccine science. If mRNA can be used to program the immune system to recognize and fight viruses, why couldn't it be adapted to target cancer cells as well?

Cancer treatment with mRNA can be a precise and versatile method. Essentially, mRNA vaccines provide genetic instructions for cells to mimic tumor-associated antigens and initiate an immune response against cancer. Because unlike traditional treatments, they need no time-consuming protein production or cell cultures to just be rapidly synthesized on a patient-by-patient basis. These are non-integrating and biodegradable, eliminating long-term safety concerns, while also features a modular design for co-delivery of multiple antigens or immunomodulatory factors in one formulation. This enables precision cancer medicine and multimodality targeted cancer therapy. Due to their particular characteristics, mRNA cancer vaccines are a truly promising platform, especially for poorly manageable cancers and in view of novel modifiable patient-specific therapies. Despite the relative infancy of this area, positive findings from early clinical trials and recent developments in delivery technologies and mechanisms to select antigens are enhancing the potential of this approach. This review examines the structural, functional, and clinical evolution of mRNA-based cancer vaccines. It highlights recent progress in RNA design, delivery strategies, and immunological innovations that are collectively reshaping the landscape of cancer treatment. While significant challenges remain, the growing momentum behind mRNA vaccine research points toward a transformative shift in oncology—one that may fundamentally change how the scientists approach cancer therapy in the future.

2. Structural optimization of mRNA cancer vaccines

The structure of mRNA vaccines is essential to stability, translation efficiency and immunogenicity. In general, the sequence of a mRNA has been divided in five main features: the 5'cap, the 5'untranslated region (UTR), Open Reading Frame (ORF), 3'UTR and poly(A) tail. All of these elements play a role in promoting effective translational and intracellular processing. According to Sahin and Türeci modifying the 5' cap structure, such as using anti-reverse cap analogs (ARCAs) or CleanCap, significantly enhances translation initiation and prevents degradation by exonucleases [1]. Similarly, optimization of the 5'and 3'UTRs with sequences originating from highly stable and efficiently translated endogenous mRNAs will enhance mRNA half-life as well as protein yield. Additionally, codon optimization in the ORF and removal of double-stranded RNA (dsRNA) impurities during purification enhance safety and efficacy of the vaccine. In addition, the substitution of naturally occurring uridine by modified nucleotides, such as N1-methylpseudouridine has been demonstrated to decrease reactogenicity and improve translation while avoiding innate immune sensing [2]. The length of the poly(A) tail is also important, with a 100–120 nucleotide tail providing the best platform for stability and recruitment of ribosomes [3]. These advancements in structural design form the foundation of next-generation mRNA cancer vaccines, enabling robust and sustained antigen expression with minimized side effects.

3. Delivery strategies and nanoparticle formulations of mRNA cancer vaccines

One of the biggest challenges for mRNA vaccine development remains delivery efficiency. Naked mRNA is also rapidly degraded by the ubiquitous RNases in extracellular environments and showed there is no cellular uptake. Hence, protective carriers are essential. Lipid nanoparticles (LNPs) have become the gold standard in mRNA delivery. As described by Hou et al., LNPs typically consist of four components: ionizable lipids, helper phospholipids, cholesterol, and PEG-lipids [4]. These structures protect mRNA during circulation, facilitate endosomal escape, and ensure efficient release into the cytoplasm. Advanced LNP formulations can also be tailored for targeted delivery to antigen-presenting cells (APCs), improving vaccine efficacy and reducing side effects. Recent studies have explored dendritic cell (DC)-targeted delivery and hybrid nanocarriers that combine lipid and polymer technologies for better immune activation [5]. Moreover, the surface charge, size, and composition of nanoparticles can be fine-tuned to enhance lymph node targeting and prolong circulation time [6]. These advancements in delivery vehicle improve bioavailability of the mRNA vaccines and increase immune cell response that is critical for successful tumor immunotherapy.

4. Immunological mechanisms and antitumor response of mRNA cancer vaccines

The effectiveness of the mRNA cancer vaccine is such that it is capable of stimulating adaptive as well as innate immunity concurrently. The mRNA is translated into tumor antigens once it is internalized by antigen-presenting cells such as dendritic cells. The antigens are processed and loaded onto major histocompatibility complex (MHC) class I and II pathways where they activate cytotoxic CD8⁺ T cells responsible for killing the tumor cells as well as helper CD4⁺ T cells [6,7]. In addition to T-cell activation, mRNA vaccines are also able to elicit robust humoral responses by activating B-cell maturation together with antigen-specific antibody generation. Dual-arm activation is important for creating sustained as well as general anti-tumor immunity with long-lasting memory able to inhibit cancer recurrence [6,8]. Recent work has focused on the calibration of the immune activation profile. For example, Krienke et al. indicated the potential for engineered mRNA vaccines to maintain the ability for immunogenicity while reducing exuberant inflammation by avoiding overexpression by proinflammatory cytokines [9]. Furthermore, the application of altered nucleosides such as N1-methyl-pseudouridine is intended to reduce recognition by pattern recognition receptors such as TLR7 or RIG-I to promote a tolerable immune profile with efficient antigen translation [2,3]. Collectively, such mechanisms position the mRNA vaccine platform as a widely capable immunotherapy for inducing specific, strong, and durable anti-tumor responses with superior safety.

5. Clinical trials and therapeutic applications of mRNA cancer vaccines in oncology

Greater proof for the possibility and effectiveness of mRNA-based cancer vaccine has emerged from clinical trials in recent times. Most notably, BioNTech's BNT111 vaccine against four antigens associated with tumors (NY-ESO-1, MAGE-A3, tyrosinase, and TPTE) exhibited lasting CD8⁺ T cell responses and superior early tumor regression in a Phase I study in melanoma [10]. Moderna's mRNA-4157/V940 given concurrently with pembrolizumab improved recurrence-free survival for patients with resected stage III/IV melanoma as demonstrated by a Phase II randomized clinical trial [11]. The combination immunotherapy's effectiveness has also stimulated Phase III trials in progress and FDA breakthrough status [11]. Moreover to melanoma, mRNA-based vaccines are also being tested in prostate, non-small cell lung, and pancreatic cancer. These trials are frequently customized

neoantigen strategies in which mRNA is engineered according to the individual patient's specific tumor mutational profile so as to permit patient-tailored immunization methods [8,12]. Respectively, such vaccines are more frequently included in combination therapies as well, particularly with the addition of immune check-point inhibitors like anti-PD-1 or agents against CTLA-4, further enhancing their clinical effectiveness [13]. The accumulating evidence favors mRNA vaccine's increasing presence in widespread mainstream oncology.

6. Limitations, challenges and future perspectives of mRNA cancer vaccines

Though mRNA cancer vaccines enjoyed explosive expansion, some serious limitations remain. Most serious is RNA molecule instability, which demands ultra-cold chains for storage and shipping, making it impractical for broad distribution [14]. Tumor heterogeneity and methods for evading the immune system also significantly diminish vaccine efficacy as tumors are programmed to down-regulate immune infiltration or vary antigen expression [8,12]. Scaling of production is also a limiting factor. Though synthetically available mRNA is available, customized cancer vaccines entail genomic sequencing, computational modeling, patient-specific formulation, which are time-consuming and expensive processes [1,3]. To address such limitations, the future prospects are the development of circular RNA (circRNA) platforms for more stable long-term expression and also integration of Artificial Intelligence (AI) for neoantigen prediction and vaccine optimization [13,15]. Apart from this, integration of mRNA vaccine with tumor microenvironment-targeting agents such as metabolic modulators or Treg depletors could favor T cell infiltration as well as T cell function [13]. Finally, the future for mRNA cancer vaccines lies in cross-disciplinary research and further clinical validation. With innovation being pushed ever more quickly by next-generation platforms and computational biology, mRNA-based therapeutics could play a significant role in personalised oncology in the coming decade [3,8].

7. Conclusion

mRNA cancer vaccines are one of the revolutionary advances in modern-day oncology. The current review assessed the evolution of mRNA vaccine technologies from structure optimization and delivery systems to mechanisms of immunology and clinical usefulness. Innovations such as CleanCap technology, UTR tuning, codon optimization, and incorporation of modified nucleosides all enhanced vaccine stability, translation efficiency, and immunogenicity. Lipid nanoparticles (LNPs) are now revealed as the ideal delivery system by delivering the mRNA to the antigen-presenting cells with the capability to elicit vigorous T cells as well as B cells. Clinical data also showed encouraging results. For example, BioNTech's BNT111 and Moderna's mRNA-4157/V940 demonstrated early effectiveness in clinical testing against melanoma, and studies are rapidly progressing to additional cancer indications. These platforms both enable tumor-selective immune stimulation as well as allow for inclusion of personalized neoantigens for individualized therapeutics. But many challenges are present. These include mRNA instability, high cost of production, short shelf life, and tumor heterogeneity. These require multidisciplinary methods for them to be overcome. A bright spot for the future is the employment of circular RNA for longacting antigen expression as well as the use of Artificial Intelligence (AI) for neoantigen prediction optimisation and vaccine design. Overall, mRNA cancer vaccines offer a very modular, safe, and rapidly adaptable platform. With continued innovation, they are poised to play a critical role in personalized cancer immunotherapy, ultimately defining cancer treatment in the coming decades.

References

- [1] Sahin, U. and Türeci, Ö. (2023) mRNA-based therapeutics—Developing a new class of drugs. *Nature Reviews Drug Discovery*, 22, 101–122.
- [2] Pardi, N., Hogan, M. J. and Weissman, D. (2020) Recent advances in mRNA vaccine technology. *Current Opinion in Immunology*, 65, 14–20.
- [3] Liu, M. A. (2023) A comparison of plasmid DNA and mRNA as vaccine technologies. *Vaccines*, 11, 1–17.
- [4] Hou, X., Zaks, T., Langer, R. and Dong, Y. (2021) Lipid nanoparticles for mRNA delivery. *Nature Reviews Materials*, 6, 1078–1094.
- [5] Luo, H., Ye, J. and Xu, J. (2024) Emerging prospects of mRNA cancer vaccines. *Cancer Cell Research Journal*, 30, 45–56.
- [6] Chaudhary, N., Weissman, D. and Whitehead, K. A. (2021) mRNA vaccines for infectious diseases: Principles, delivery and clinical translation. *Nature Reviews Drug Discovery*, 20, 817–838.
- [7] Huang, S., Que, H., Wang, M. and Wei, X. (2024) mRNA vaccines as cancer therapies. *Chinese Medical Journal*, 137, 2979–2995.
- [8] Laila, U. E., An, W. and Xu, Z.X. (2024) Emerging prospects of mRNA cancer vaccines: Mechanisms, formulations, and challenges in cancer immunotherapy. *Frontiers in Immunology*, 15, 1448489.
- [9] Krienke, C., Kolb, L., Diken, E., Streuber, M., Kirchhoff, S., Bukur, T., Akilli-Öztürk, Ö., Kranz, L.M., Berger, H., Petschenka, J., Diken, M., Kreiter, S., Yorgev, N., Waisman, A., Karikó, K., Türeci Ö and Sahin U. (2021) A noninflammatory mRNA vaccine for treatment of experimental autoimmune encephalomyelitis. *Science*, 371, 145153.
- [10] Zhao, H., Liu, Z. and Liu, X. (2024) The recent research progress of the tumor mRNA vaccine. *Vaccines*, 12, 1167.
- [11] Liu, M., Li, X., Zhou, Y. and Wang, H. (2024) mRNA cancer vaccines from bench to bedside. *Frontiers in Oncology*, 14, 1304212.
- [12] Chen, B., Yang, Y., Wang, X., Yang, W., Lu, Y., Wang, D., Zhuo, E., Tang, Y., Su, J., Tang, G., Shao, S. and Gu, K. (2024) mRNA vaccine development and applications: A special focus on tumors. *International Journal of Oncology*, 65, 81.
- [13] Shariati, A., Khani, P., Nasri, F., Afkhami, H., Khezrpour, A., Kamrani, S., Shariati, F., Alavimanesh, S. and Modarressi, M.H. (2024) mRNA cancer vaccines from bench to bedside: A new era in cancer immunotherapy. *Biomarker Research*, 12, 157.
- [14] Zhang, C., Maruggi, G., Shan, H. and Li, J. (2020) Advances in mRNA vaccines for infectious diseases. *Frontiers in Immunology*, 11, 594710.
- [15] Feng, Z., Zhang, X., Zhou, J., Li, Q., Chu, L., Di, G., Xu, Z., Chen, Q., Wang, M., Jiang, X., Xia, H. and Chen, X. (2024) An in vitro-transcribed circular RNA targets the mitochondrial inner membrane cardiolipin to ablate EIF4G2(+)/PTBP1(+) pan-adenocarcinoma. *Nature Cancer*, 5, 30–46.